$DFCO
DALRADA FINANCIAL CORP Stock $dfco

$dfco Overview Financials Valuation SEC Filings Company Website

2022 Q3 Form 10-K Financial Statement

#000168316822007171 Filed on November 01, 2022

Income Statement

Concept	2022 Q3	2022 Q2	2022
Revenue	$4.258M	$3.626M	$19.27M
YoY Change	-7.49%	104997.1%	465.58%
Cost Of Revenue	$2.356M	$3.727M	$8.761M
YoY Change	95.65%	302.95%	254.42%
Gross Profit	$1.901M	-$101.1K	$10.51M
YoY Change	-44.04%	-89.03%	1024.02%
Gross Profit Margin	44.66%	-2.79%	54.53%
Selling, General & Admin	$4.858M	$3.955M	$20.07M
YoY Change	15.44%	18.4%	123.35%
% of Gross Profit	255.47%		190.99%
Research & Development	$0.00	$655.4K	$657.0K
YoY Change	-100.0%	463.74%	26.22%
% of Gross Profit	0.0%		6.25%
Depreciation & Amortization	$43.66K	$166.1K	$252.9K
YoY Change	4.85%	59.62%	78.89%
% of Gross Profit	2.3%		2.41%
Operating Expenses	$4.858M	$4.759M	$20.94M
YoY Change	12.71%	37.7%	120.33%
Operating Profit	-$2.956M	-$4.861M	-$10.44M
YoY Change	224.19%	11.02%	21.76%
Interest Expense	$672.1K	-$660.9K	$1.304M
YoY Change	-945.23%	344.39%	-318.35%
% of Operating Profit
Other Income/Expense, Net	-$214.0K	$338.0K	-$1.004M
YoY Change	-1554.78%	338.04%	-977.65%
Pretax Income	-$3.170M	-$5.402M	-$11.44M
YoY Change	224.59%	-217.32%	-937745.08%
Income Tax	$0.00	$132.5K	$132.5K
% Of Pretax Income
Net Earnings	-$3.618M	-$5.024M	-$14.10M
YoY Change	59.67%	-207.57%	-15519.79%
Net Earnings / Revenue	-84.97%	-138.56%	-73.17%
Basic Earnings Per Share	-$0.05		-$0.20
Diluted Earnings Per Share	-$0.05	-$71.05K	-$0.20
COMMON SHARES
Basic Shares Outstanding	79.99M shares		72.22M shares
Diluted Shares Outstanding	72.22M shares		72.22M shares

Balance Sheet

Concept	2022 Q3	2022 Q2	2022
SHORT-TERM ASSETS
Cash & Short-Term Investments	$936.3K	$891.9K	$891.9K
YoY Change	913.92%	708.64%	708.64%
Cash & Equivalents	$936.3K	$772.1K	$891.9K
Short-Term Investments
Other Short-Term Assets	$1.178M	$430.1K	$430.1K
YoY Change	278.09%	50.89%	50.89%
Inventory	$1.647M	$1.625M	$1.625M
Prepaid Expenses
Receivables	$5.979M	$6.407M	$6.328M
Other Receivables	$552.3K	$288.7K	$288.7K
Total Short-Term Assets	$10.43M	$9.564M	$9.564M
YoY Change	77.21%	482.96%	482.96%
LONG-TERM ASSETS
Property, Plant & Equipment	$1.374M	$1.076M	$3.829M
YoY Change	7.37%	-35.22%	130.44%
Goodwill	$4.253M	$4.253M
YoY Change		477.55%
Intangibles	$3.530M	$3.525M
YoY Change		430.46%
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets	$14.56M	$12.86M	$12.86M
YoY Change	427.9%	319.87%	319.87%
TOTAL ASSETS
Total Short-Term Assets	$10.43M	$9.564M	$9.564M
Total Long-Term Assets	$14.56M	$12.86M	$12.86M
Total Assets	$25.00M	$22.42M	$22.42M
YoY Change	189.09%	376.76%	376.76%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$2.095M	$2.332M	$2.332M
YoY Change	194.65%	156.11%	156.11%
Accrued Expenses	$3.128M	$1.799M	$4.660M
YoY Change	-6.87%	-38.38%	59.58%
Deferred Revenue	$696.2K	$720.9K
YoY Change		227.69%
Short-Term Debt	$13.17M	$10.76M	$10.76M
YoY Change	3152.86%	-15.9%	-15.9%
Long-Term Debt Due	$622.8K	$669.0K	$669.0K
YoY Change		60.89%	60.89%
Total Short-Term Liabilities	$23.90M	$20.42M	$20.42M
YoY Change	337.79%	18.26%	18.26%
LONG-TERM LIABILITIES
Long-Term Debt	$9.755M	$10.14M	$10.14M
YoY Change	-1.25%
Other Long-Term Liabilities	$7.646M	$6.821M	$6.821M
YoY Change	2556.54%	706.11%	706.11%
Total Long-Term Liabilities	$17.40M	$16.96M	$16.96M
YoY Change	71.16%	1904.32%	1904.32%
TOTAL LIABILITIES
Total Short-Term Liabilities	$23.90M	$20.42M	$20.42M
Total Long-Term Liabilities	$17.40M	$16.96M	$16.96M
Total Liabilities	$41.30M	$37.38M	$37.85M
YoY Change	143.13%	106.81%	109.46%
SHAREHOLDERS EQUITY
Retained Earnings	-$125.1M	-$121.4M
YoY Change		13.13%
Common Stock	$401.6K	$360.9K
YoY Change		-2.26%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$17.23M	-$15.43M	-$15.43M
YoY Change
Total Liabilities & Shareholders Equity	$25.00M	$22.42M	$22.42M
YoY Change	189.09%	376.76%	376.76%

Cashflow Statement

Concept	2022 Q3	2022 Q2	2022
OPERATING ACTIVITIES
Net Income	-$3.618M	-$5.024M	-$14.10M
YoY Change	59.67%	-207.57%	-15519.79%
Depreciation, Depletion And Amortization	$43.66K	$166.1K	$252.9K
YoY Change	4.85%	59.62%	78.89%
Cash From Operating Activities	-$1.208M	-$2.783M	-$10.35M
YoY Change	-62.41%	47.97%	85.35%
INVESTING ACTIVITIES
Capital Expenditures	$341.5K	-$234.7K	$640.2K
YoY Change	-256.76%	7.21%	-278.84%
Acquisitions
YoY Change
Other Investing Activities		$308.2K	$308.2K
YoY Change		-414.5%	-1205.88%
Cash From Investing Activities	-$429.5K	$73.55K	-$574.0K
YoY Change	97.15%	-123.21%	48.78%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	$2.642M	3.052M	$11.67M
YoY Change	-21.69%	51.75%	95.63%
NET CHANGE
Cash From Operating Activities	-$1.208M	-2.783M	-$10.35M
Cash From Investing Activities	-$429.5K	73.55K	-$574.0K
Cash From Financing Activities	$2.642M	3.052M	$11.67M
Net Change In Cash	$1.005M	342.4K	$744.7K
YoY Change	-1853.48%	-283.61%	-14789.09%
FREE CASH FLOW
Cash From Operating Activities	-$1.208M	-$2.783M	-$10.35M
Capital Expenditures	$341.5K	-$234.7K	$640.2K
Free Cash Flow	-$1.549M	-$2.549M	-$10.99M
YoY Change	-48.27%	53.34%	110.3%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2022	dei	Entity Address City Or Town EntityAddressCityOrTown	Escondido
CY2022	dei	Entity Address State Or Province EntityAddressStateOrProvince	CA
CY2022	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	92025
CY2022	dei	City Area Code CityAreaCode	858
CY2022	dei	Local Phone Number LocalPhoneNumber	283-1253
CY2022	dei	Security12b Title Security12bTitle	Common Stock, $0.005 par value per share
CY2022	dei	Trading Symbol TradingSymbol	DFCO
CY2022	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2022	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2022	dei	Entity Current Reporting Status EntityCurrentReportingStatus	No
CY2022	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	No
CY2022	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2022	dei	Entity Small Business EntitySmallBusiness	true
CY2022	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2022	dei	Entity Shell Company EntityShellCompany	false
CY2022Q2	dei	Entity Public Float EntityPublicFloat	46878846	usd
CY2022Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	79987641	shares
CY2022	dei	Auditor Name AuditorName	dbbmckennon
CY2022	dei	Auditor Location AuditorLocation	San Diego, California
CY2022	dei	Auditor Firm AuditorFirmId	3501
CY2022Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	772062	usd
CY2021Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	110285	usd
CY2022Q2	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	6406555	usd
CY2021Q2	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	265812	usd
CY2022Q2	us-gaap	Accounts Receivable Related Parties Current AccountsReceivableRelatedPartiesCurrent	41603	usd
CY2021Q2	us-gaap	Accounts Receivable Related Parties Current AccountsReceivableRelatedPartiesCurrent	69952	usd
CY2022Q2	us-gaap	Other Receivables Net Current OtherReceivablesNetCurrent	288655	usd
CY2021Q2	us-gaap	Other Receivables Net Current OtherReceivablesNetCurrent	67328	usd
CY2022	dei	Entity Central Index Key EntityCentralIndexKey	0000725394
CY2022	dei	Amendment Flag AmendmentFlag	false
CY2022	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
CY2022	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2022Q2	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2021Q2	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2021Q2	us-gaap	Business Combination Contingent Consideration Liability BusinessCombinationContingentConsiderationLiability		usd
CY2021	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit		usd
CY2022	dei	Document Type DocumentType	10-K
CY2022	dei	Document Annual Report DocumentAnnualReport	true
CY2022	dei	Document Period End Date DocumentPeriodEndDate	2022-06-30
CY2022	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--06-30
CY2022	dei	Document Transition Report DocumentTransitionReport	false
CY2022	dei	Entity File Number EntityFileNumber	000-12641
CY2022	dei	Entity Registrant Name EntityRegistrantName	DALRADA FINANCIAL CORPORATION
CY2022	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	WY
CY2022	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	38-3713274
CY2022	dei	Entity Address Address Line1 EntityAddressAddressLine1	600 La Terraza Blvd.
CY2022Q2	us-gaap	Inventory Net InventoryNet	1624621	usd
CY2021Q2	us-gaap	Inventory Net InventoryNet	842108	usd
CY2022Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	430070	usd
CY2021Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	285026	usd
CY2022Q2	us-gaap	Assets Current AssetsCurrent	9563566	usd
CY2021Q2	us-gaap	Assets Current AssetsCurrent	1640511	usd
CY2022Q2	us-gaap	Long Term Investments And Receivables Net LongTermInvestmentsAndReceivablesNet	42395	usd
CY2021Q2	us-gaap	Long Term Investments And Receivables Net LongTermInvestmentsAndReceivablesNet	0	usd
CY2022Q2	DFCO	Longterm Receivables Related Parties LongtermReceivablesRelatedParties	1209103	usd
CY2021Q2	DFCO	Longterm Receivables Related Parties LongtermReceivablesRelatedParties	0	usd
CY2022Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1076412	usd
CY2021Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	489902	usd
CY2022Q2	us-gaap	Goodwill Goodwill	4253424	usd
CY2021Q2	us-gaap	Goodwill Goodwill	736456	usd
CY2022Q2	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	3524888	usd
CY2021Q2	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	664494	usd
CY2022Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1665436	usd
CY2021Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	532327	usd
CY2022Q2	DFCO	Right Of Use Asset Net Related Party RightOfUseAssetNetRelatedParty	1087256	usd
CY2021Q2	DFCO	Right Of Use Asset Net Related Party RightOfUseAssetNetRelatedParty	639415	usd
CY2022Q2	us-gaap	Assets Assets	22422480	usd
CY2021Q2	us-gaap	Assets Assets	4703105	usd
CY2022Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	2331919	usd
CY2021Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	910339	usd
CY2022Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1799404	usd
CY2021Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	641380	usd
CY2022Q2	us-gaap	Accrued Payroll Taxes Current AccruedPayrollTaxesCurrent	2055736	usd
CY2021Q2	us-gaap	Accrued Payroll Taxes Current AccruedPayrollTaxesCurrent	1953024	usd
CY2022Q2	us-gaap	Accounts Payable Related Parties Current AccountsPayableRelatedPartiesCurrent	1270133	usd
CY2021Q2	us-gaap	Accounts Payable Related Parties Current AccountsPayableRelatedPartiesCurrent	414237	usd
CY2022Q2	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	720923	usd
CY2021Q2	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	219999	usd
CY2022Q2	us-gaap	Other Notes Payable Current OtherNotesPayableCurrent	669028	usd
CY2021Q2	us-gaap	Other Notes Payable Current OtherNotesPayableCurrent	415817	usd
CY2022Q2	us-gaap	Notes Payable Related Parties Classified Current NotesPayableRelatedPartiesClassifiedCurrent	9269377	usd
CY2021Q2	us-gaap	Notes Payable Related Parties Classified Current NotesPayableRelatedPartiesClassifiedCurrent	10508955	usd
CY2022Q2	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent	0	usd
CY2021Q2	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent	1875000	usd
CY2022Q2	DFCO	Convertible Notes Payable Net Of Debt Discount ConvertibleNotesPayableNetOfDebtDiscount	1495528	usd
CY2021Q2	DFCO	Convertible Notes Payable Net Of Debt Discount ConvertibleNotesPayableNetOfDebtDiscount	0	usd
CY2022Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	435647	usd
CY2021Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	76570	usd
CY2022Q2	DFCO	Right Of Use Liability Related Party Current RightOfUseLiabilityRelatedPartyCurrent	369050	usd
CY2021Q2	DFCO	Right Of Use Liability Related Party Current RightOfUseLiabilityRelatedPartyCurrent	159790	usd
CY2022Q2	us-gaap	Liabilities Current LiabilitiesCurrent	20416745	usd
CY2021Q2	us-gaap	Liabilities Current LiabilitiesCurrent	17175111	usd
CY2022Q2	us-gaap	Long Term Loans Payable LongTermLoansPayable	120534	usd
CY2021Q2	us-gaap	Long Term Loans Payable LongTermLoansPayable	0	usd
CY2022Q2	us-gaap	Long Term Notes Payable LongTermNotesPayable	479001	usd
CY2021Q2	us-gaap	Long Term Notes Payable LongTermNotesPayable	0	usd
CY2022Q2	us-gaap	Notes Payable Related Parties Noncurrent NotesPayableRelatedPartiesNoncurrent	9538685	usd
CY2021Q2	us-gaap	Notes Payable Related Parties Noncurrent NotesPayableRelatedPartiesNoncurrent	0	usd
CY2022Q2	DFCO	Contingent Consideration ContingentConsideration	4870800	usd
CY2021Q2	DFCO	Contingent Consideration ContingentConsideration	0	usd
CY2022Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1231691	usd
CY2021Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	455757	usd
CY2022Q2	DFCO	Right Of Use Liability Related Party Non Current RightOfUseLiabilityRelatedPartyNonCurrent	718206	usd
CY2021Q2	DFCO	Right Of Use Liability Related Party Non Current RightOfUseLiabilityRelatedPartyNonCurrent	479625	usd
CY2022Q2	us-gaap	Liabilities Liabilities	37375662	usd
CY2021Q2	us-gaap	Liabilities Liabilities	18110493	usd
CY2022Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.005
CY2021Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.005
CY2022Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	1000000000	shares
CY2021Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	1000000000	shares
CY2022Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	72174620	shares
CY2022Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	72174620	shares
CY2021Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	73838662	shares
CY2021Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	73838662	shares
CY2022Q2	us-gaap	Common Stock Value CommonStockValue	360855	usd
CY2021Q2	us-gaap	Common Stock Value CommonStockValue	369194	usd
CY2022Q2	DFCO	Common Stock To Be Issued CommonStockToBeIssued	1066925	usd
CY2021Q2	DFCO	Common Stock To Be Issued CommonStockToBeIssued	601825	usd
CY2022Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	104627032	usd
CY2021Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	92965821	usd
CY2022Q2	us-gaap	Minority Interest MinorityInterest	479019	usd
CY2021Q2	us-gaap	Minority Interest MinorityInterest	-38391	usd
CY2022Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-121436490	usd
CY2021Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-107338174	usd
CY2022Q2	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-50673	usd
CY2021Q2	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	32287	usd
CY2022Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-14953182	usd
CY2021Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-13407388	usd
CY2022Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	22422480	usd
CY2021Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	4703105	usd
CY2022	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	19267613	usd
CY2021	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	3406684	usd
CY2022	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	8761266	usd
CY2021	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	2471966	usd
CY2022	us-gaap	Gross Profit GrossProfit	10506347	usd
CY2021	us-gaap	Gross Profit GrossProfit	934718	usd
CY2022	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	2772770	usd
CY2021	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	801672	usd
CY2022	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	20066286	usd
CY2021	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	8984359	usd
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	656997	usd
CY2021	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	520510	usd
CY2022	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	218308	usd
CY2021	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0	usd
CY2022	us-gaap	Operating Expenses OperatingExpenses	20941591	usd
CY2021	us-gaap	Operating Expenses OperatingExpenses	9504869	usd
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-10435244	usd
CY2021	us-gaap	Operating Income Loss OperatingIncomeLoss	-8570151	usd
CY2022	us-gaap	Interest Expense InterestExpense	1303714	usd
CY2021	us-gaap	Interest Expense InterestExpense	670272	usd
CY2022	us-gaap	Interest Income Operating InterestIncomeOperating	4451	usd
CY2021	us-gaap	Interest Income Operating InterestIncomeOperating	6278	usd
CY2022	us-gaap	Other Income OtherIncome	308534	usd
CY2021	us-gaap	Other Income OtherIncome	114401	usd
CY2022	DFCO	Gain On Expiration Of Accrued Tax Liability GainOnExpirationOfAccruedTaxLiability	0	usd
CY2021	DFCO	Gain On Expiration Of Accrued Tax Liability GainOnExpirationOfAccruedTaxLiability	9054041	usd
CY2022	us-gaap	Foreign Currency Transaction Gain Loss Realized ForeignCurrencyTransactionGainLossRealized	-13297	usd
CY2021	us-gaap	Foreign Currency Transaction Gain Loss Realized ForeignCurrencyTransactionGainLossRealized	66924	usd
CY2022	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-1004026	usd
CY2021	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	8571372	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-11439270	usd
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	1221	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	132513	usd
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2022	us-gaap	Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest	-11571783	usd
CY2021	us-gaap	Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest	1221	usd
CY2022	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	2526533	usd
CY2021	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-90212	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-14098316	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	91433	usd
CY2022	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-82960	usd
CY2021	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	40184	usd
CY2022	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-11654743	usd
CY2021	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	41405	usd
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.20
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.20
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.00
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.00
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	72217851	shares
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	70318073	shares
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	72217851	shares
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	128946367	shares
CY2020Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-15138435	usd
CY2021	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	730000	usd
CY2021	DFCO	Common Stock Issued Pursuant To Business Combinations CommonStockIssuedPursuantToBusinessCombinations	887969	usd
CY2021	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	71673	usd
CY2021	us-gaap	Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest	1221	usd
CY2021	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-40184	usd
CY2021Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-13407388	usd
CY2022	us-gaap	Debt Conversion Converted Instrument Amount1 DebtConversionConvertedInstrumentAmount1	6532206	usd
CY2022	us-gaap	Stock Issued During Period Value Acquisitions StockIssuedDuringPeriodValueAcquisitions	1093003	usd
CY2022	DFCO	Joint Venture JointVenture	-1950563	usd
CY2022	DFCO	Reversal Of Shares Previously Issued To Directors ReversalOfSharesPreviouslyIssuedToDirectors	-14826	usd
CY2022	DFCO	Common Stock And Warrants Issued In Connection With Convertible Note CommonStockAndWarrantsIssuedInConnectionWithConvertibleNote	1542695	usd
CY2022	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	133664	usd
CY2022	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	2772770	usd
CY2022	us-gaap	Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest	-11571783	usd
CY2022	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	82960	usd
CY2022Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-14953182	usd
CY2022	us-gaap	Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest	-11571783	usd
CY2021	us-gaap	Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest	1221	usd
CY2022	us-gaap	Depreciation And Amortization DepreciationAndAmortization	323018	usd
CY2021	us-gaap	Depreciation And Amortization DepreciationAndAmortization	141388	usd
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	2772770	usd
CY2021	us-gaap	Share Based Compensation ShareBasedCompensation	801672	usd
CY2022	DFCO	Bad Debt Expense BadDebtExpense	1659559	usd
CY2021	DFCO	Bad Debt Expense BadDebtExpense	0	usd
CY2022	DFCO	Change In Fair Value Of Contingent Consideration ChangeInFairValueOfContingentConsideration	-182200	usd
CY2021	DFCO	Change In Fair Value Of Contingent Consideration ChangeInFairValueOfContingentConsideration	0	usd
CY2022	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	554970	usd
CY2021	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	0	usd
CY2022	DFCO	Convertible Debt Premium Satisfied With Common Stock ConvertibleDebtPremiumSatisfiedWithCommonStock	20000	usd
CY2021	DFCO	Convertible Debt Premium Satisfied With Common Stock ConvertibleDebtPremiumSatisfiedWithCommonStock	0	usd
CY2022	DFCO	Noncash Research And Development Expenses NoncashResearchAndDevelopmentExpenses	0	usd
CY2021	DFCO	Noncash Research And Development Expenses NoncashResearchAndDevelopmentExpenses	113969	usd
CY2022	DFCO	Gain On Expiration Of Accrued Tax Liabilities GainOnExpirationOfAccruedTaxLiabilities	-0	usd
CY2021	DFCO	Gain On Expiration Of Accrued Tax Liabilities GainOnExpirationOfAccruedTaxLiabilities	9054041	usd
CY2022	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-0	usd
CY2021	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	78479	usd
CY2022	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	218308	usd
CY2021	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0	usd
CY2022	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	7383296	usd
CY2021	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-29274	usd
CY2022	us-gaap	Increase Decrease In Other Receivables IncreaseDecreaseInOtherReceivables	221327	usd
CY2021	us-gaap	Increase Decrease In Other Receivables IncreaseDecreaseInOtherReceivables	-11685	usd
CY2022	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	608657	usd
CY2021	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	191686	usd
CY2022	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	137767	usd
CY2021	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	133613	usd
CY2022	us-gaap	Increase Decrease In Long Term Receivables Current IncreaseDecreaseInLongTermReceivablesCurrent	1251498	usd
CY2021	us-gaap	Increase Decrease In Long Term Receivables Current IncreaseDecreaseInLongTermReceivablesCurrent	-0	usd
CY2022	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	1116618	usd
CY2021	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	563338	usd
CY2022	DFCO	Increase Decrease In Longterm Payables IncreaseDecreaseInLongtermPayables	120534	usd
CY2021	DFCO	Increase Decrease In Longterm Payables IncreaseDecreaseInLongtermPayables	0	usd
CY2022	us-gaap	Increase Decrease In Due To Related Parties IncreaseDecreaseInDueToRelatedParties	2405364	usd
CY2021	us-gaap	Increase Decrease In Due To Related Parties IncreaseDecreaseInDueToRelatedParties	1345875	usd
CY2022	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	1211943	usd
CY2021	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	370789	usd
CY2022	us-gaap	Increase Decrease In Accrued Taxes Payable IncreaseDecreaseInAccruedTaxesPayable	102712	usd
CY2021	us-gaap	Increase Decrease In Accrued Taxes Payable IncreaseDecreaseInAccruedTaxesPayable	487625	usd
CY2022	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	500924	usd
CY2021	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	7194	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-10349808	usd
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-5583788	usd
CY2022	DFCO	Net Cash Received Paid In Business Combinations NetCashReceivedPaidInBusinessCombinations	-308207	usd
CY2021	DFCO	Net Cash Received Paid In Business Combinations NetCashReceivedPaidInBusinessCombinations	27869	usd
CY2022	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	640184	usd
CY2021	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	357961	usd
CY2022	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	242063	usd
CY2021	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	-0	usd
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-574040	usd
CY2021	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-385830	usd
CY2022	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	11492218	usd
CY2021	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	5967054	usd
CY2022	us-gaap	Repayments Of Related Party Debt RepaymentsOfRelatedPartyDebt	233556	usd
CY2021	us-gaap	Repayments Of Related Party Debt RepaymentsOfRelatedPartyDebt	-0	usd
CY2022	us-gaap	Proceeds From Repayments Of Notes Payable ProceedsFromRepaymentsOfNotesPayable	-34943	usd
CY2021	us-gaap	Proceeds From Repayments Of Notes Payable ProceedsFromRepaymentsOfNotesPayable	-2500	usd
CY2022	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	2880000	usd
CY2021	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	0	usd
CY2022	us-gaap	Repayments Of Convertible Debt RepaymentsOfConvertibleDebt	300000	usd
CY2021	us-gaap	Repayments Of Convertible Debt RepaymentsOfConvertibleDebt	-0	usd
CY2022	us-gaap	Payments Of Dividends Minority Interest PaymentsOfDividendsMinorityInterest	2120308	usd
CY2021	us-gaap	Payments Of Dividends Minority Interest PaymentsOfDividendsMinorityInterest	-0	usd
CY2022	DFCO	Repurchase Of Common Shares From Subsidiary RepurchaseOfCommonSharesFromSubsidiary	14826	usd
CY2021	DFCO	Repurchase Of Common Shares From Subsidiary RepurchaseOfCommonSharesFromSubsidiary	-0	usd
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	11668585	usd
CY2021	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	5964554	usd
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	744737	usd
CY2021	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-5064	usd
CY2022	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-82960	usd
CY2021	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	40184	usd
CY2021Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	110285	usd
CY2020Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	75165	usd
CY2022Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	772062	usd
CY2021Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	110285	usd
CY2022	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	77766	usd
CY2021	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	0	usd
CY2022	us-gaap	Interest Paid Net InterestPaidNet	0	usd
CY2021	us-gaap	Interest Paid Net InterestPaidNet	0	usd
CY2022	DFCO	Conversion Of Related Party Notes And Interest Into Preferred Stock ConversionOfRelatedPartyNotesAndInterestIntoPreferredStock	6532206	usd
CY2021	DFCO	Conversion Of Related Party Notes And Interest Into Preferred Stock ConversionOfRelatedPartyNotesAndInterestIntoPreferredStock	0	usd
CY2022	DFCO	Contribution Of Property And Equipment Into Joint Venture ContributionOfPropertyAndEquipmentIntoJointVenture	111185	usd
CY2021	DFCO	Contribution Of Property And Equipment Into Joint Venture ContributionOfPropertyAndEquipmentIntoJointVenture	0	usd
CY2022	DFCO	Issuance Of Shares To Joint Venture Partner IssuanceOfSharesToJointVenturePartner	58560	usd
CY2021	DFCO	Issuance Of Shares To Joint Venture Partner IssuanceOfSharesToJointVenturePartner	0	usd
CY2022	DFCO	Conversion Of Accounts Payable Related Parties To Notes Payable Related Parties ConversionOfAccountsPayableRelatedPartiesToNotesPayableRelatedParties	181744	usd
CY2021	DFCO	Conversion Of Accounts Payable Related Parties To Notes Payable Related Parties ConversionOfAccountsPayableRelatedPartiesToNotesPayableRelatedParties	0	usd
CY2022	DFCO	Common Stock And Warrants Issued In Connection With Convertible Note CommonStockAndWarrantsIssuedInConnectionWithConvertibleNote	1542695	usd
CY2021	DFCO	Common Stock And Warrants Issued In Connection With Convertible Note CommonStockAndWarrantsIssuedInConnectionWithConvertibleNote	0	usd
CY2022	DFCO	Common Stock Issued Pursuant To Conversion Of Note CommonStockIssuedPursuantToConversionOfNote	133664	usd
CY2021	DFCO	Common Stock Issued Pursuant To Conversion Of Note CommonStockIssuedPursuantToConversionOfNote	0	usd
CY2022	DFCO	Common Stock Issued Pursuant To Business Combination CommonStockIssuedPursuantToBusinessCombination	1093003	usd
CY2021	DFCO	Common Stock Issued Pursuant To Business Combination CommonStockIssuedPursuantToBusinessCombination	887969	usd
CY2022	DFCO	Fair Value Of Assets Acquired And Liabilities Assumed In Acquisition FairValueOfAssetsAcquiredAndLiabilitiesAssumedInAcquisition	468232	usd
CY2021	DFCO	Fair Value Of Assets Acquired And Liabilities Assumed In Acquisition FairValueOfAssetsAcquiredAndLiabilitiesAssumedInAcquisition	-200696	usd
CY2022	DFCO	Conversion Of Accounts Payable Related Parties To Related Parties Convertible Notes ConversionOfAccountsPayableRelatedPartiesToRelatedPartiesConvertibleNotes	0	usd
CY2021	DFCO	Conversion Of Accounts Payable Related Parties To Related Parties Convertible Notes ConversionOfAccountsPayableRelatedPartiesToRelatedPartiesConvertibleNotes	1488119	usd
CY2022	DFCO	Outstanding Balance Of Note Payable Issued For Due To Seller Payment OutstandingBalanceOfNotePayableIssuedForDueToSellerPayment	0	usd
CY2021	DFCO	Outstanding Balance Of Note Payable Issued For Due To Seller Payment OutstandingBalanceOfNotePayableIssuedForDueToSellerPayment	98000	usd
CY2022	us-gaap	Nature Of Operations NatureOfOperations	<p id="xdx_800_eus-gaap--NatureOfOperations_zK1Nr6Tewfj8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>1.</b></span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_821_zzB3XkeTss5f">Organization and Nature of Operations </span></b></span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Dalrada Financial Corporation, (“Dalrada”), was incorporated in September 1982 under the laws of the State of California. It was reincorporated in May 1983 under the laws of the State of Delaware and reincorporated again on May 5, 2020, under the laws of the state of Wyoming. Dalrada Financial Corporation trades under the symbol, OTCQB: DFCO.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">In June 2018, the Company created a new subsidiary, Dalrada Precision Corp. (“Dalrada Precision”). Dalrada Precision was formed to provide manufacturing solutions which start with the design and development of high-quality machine parts and components, and end with an efficient global supply chain.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">In October 2018, the Company created a new subsidiary, Dalrada Health Products Corp (“Dalrada Health”) for the distribution of medical disposables, hospital equipment and furniture, medical devices, laboratory and dental products, and sanitizing, disinfectant and PPE products & services.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">On December 6, 2019, Dalrada, via its wholly owned subsidiary, Dalrada Precision, acquired 100% of the issued and outstanding shares of Likido Ltd. (HQ), a United Kingdom company (“Likido”). Likido is an international technology company developing advanced solutions for the harvesting and recycling of energy.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">On January 9, 2020, Dalrada acquired 72% of the issued and outstanding shares of Prakat Solutions Inc. a Texas corporation, (“Prakat”). Prakat provides global customers with software and technology solutions specializing in Test Engineering,</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">On or about March 23, 2020, Dalrada Health acquired 100% of the issued and outstanding shares of Shark Innovative Technologies Corp. (“Shark”). Shark is a cleaning solutions provider using electrostatic machines to spray and deodorize residential spaces, healthcare facilities, hospitality, transportation, manufacturing, automotive, schools/education systems, and other facilities requiring cleaning services.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">On January 29, 2021, Dalrada Health acquired 100% of the issued and outstanding shares of International Health Group, Inc., a California corporation (“IHG”). IHG provides highly trained nursing and medical assistants for hospitals and home health facilities since 2006. IHG Medical Assistant programs include CNA (“Certified Nursing Assistant”) and HHA (“Home Health Aide”) training and the fast-track 22-Day CNA Certification Program at its state-approved testing facility (see “Note 4. Business Combinations and Acquisition” for additional information).</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">On February 3, 2021, Dalrada Health acquired 100% of the limited liability units of Pacific Stem Cells, LLC, a California limited liability company (“Pacific Stem”). Pacific Stem provides regenerative therapy as a potential solution for the prevention, detection, and treatment of cellular breakdown associated with aging and a variety of other conditions (see “Note 4. Business Combinations and Acquisition” for additional information).</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">On April 21, 2021, the Company acquired 100% of the limited liability units of Ignite IT LLC, a Wisconsin limited liability company (“Ignite”). Ignite is a manufacturer and seller of eco-friendly deep cleaners, parts washers and degreasers that are specially formulated to lift hydrocarbon-based dirt and grease (see “Note 4. Business Combinations and Acquisition” for additional information).</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">In June 2021, the Company launched Empower Genomics Corp. (“Empower”) to enter the genetic and diagnostics testing industry.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">In June 2021, the Company launched Solas Corp. (“Solas”) as an end-to-end management and oversight company for health and wellness practices throughout the California.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">On July 23, 2021, the Company, through Dalrada Health, entered into a Limited Liability Company Agreement, for a 51% membership interest, with Pala Diagnostics, LLC, a California limited liability company (“Pala”). Pala was formed to provide diagnostic testing, specifically COVID-19.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">On April 7, 2022, the Company acquired 100% of the issued and outstanding shares of Silicon Services Consortium (Europe) LTD, a United Kingdom company (“DepTec”). DepTec designs, develops, manufactures, and services chemical vapor and physical vapor deposition systems for the microchip and semiconductor industries (see “Note 4. Business Combinations and Acquisition” for additional information).</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">On June 7, 2022, the Company acquired 100% of the limited liability units of RxHealth LLC, a Louisiana limited liability company (“Watson”). Watson specializes in providing expert care and managing disease states through comprehensive prescription management, education, nursing, and total health solutions (see “Note 4. Business Combinations and Acquisition” for additional information).</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The Company's principal executive offices are located at 600 La Terraza Blvd., Escondido, California 92025.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><i><span style="text-decoration: underline">Going Concern</span></i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><i> </i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">These consolidated financial statements have been prepared on a going concern basis, which implies that the Company will continue to realize its assets and discharge its liabilities in the normal course of business. As of June 30, 2022, the Company had a working capital deficit of $<span id="xdx_906_ecustom--WorkingCapital_c20220630_pp0p0" title="Working capital deficit">9,357,651</span> and an accumulated deficit of $<span id="xdx_902_eus-gaap--RetainedEarningsAccumulatedDeficit_iNI_pp0p0_di_c20220630_zfjXHAGafjl9" title="Accumulated deficit">121,436,490</span>. The Company incurred negative cash flows from operations for the years ended June 30, 2022, and 2021, and raises substantial doubt about the Company’s ability to continue as a going concern. The continuation of the Company as a going concern is dependent upon the successful financing through equity and/or debt investors and growing the subsidiaries anticipated to be profitable while reducing investments in areas that are not expected to have long-term benefits. The Company expects to fund any short-term operational deficits through collection of outstanding accounts receivable from HRSA, insurance providers, the sale of Likido units as well as loans from related parties.</p>
CY2022Q2	DFCO	Working Capital WorkingCapital	9357651	usd
CY2022Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-121436490	usd
CY2022Q2	us-gaap	Derivative Fair Value Of Derivative Net DerivativeFairValueOfDerivativeNet	4870800	usd
CY2022Q2	us-gaap	Derivative Fair Value Of Derivative Net DerivativeFairValueOfDerivativeNet	4870800	usd
CY2022	us-gaap	Use Of Estimates UseOfEstimates	<p id="xdx_846_eus-gaap--UseOfEstimates_z6rGhIyA4Edf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 0.5in"> </td> <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_86F_z9OXrYpvVB3">Use of Estimates</span></span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The preparation of these consolidated financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. The Company regularly evaluates estimates and assumptions related to the revenue, valuation of inventory, valuation of accrued payroll tax liabilities, valuation of acquired assets and liabilities, variables used in the computation of share-based compensation, litigation, and evaluation of goodwill and intangible assets for impairment.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The Company bases its estimates and assumptions on current facts, historical experience, and various other factors that it believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the accrual of costs and expenses that are not readily apparent from other sources. The actual results experienced by the Company may differ materially and adversely from the Company’s estimates. To the extent there are material differences between the estimates and the actual results, future results of operations will be affected.</p>
CY2021	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	58628294	shares
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	128946367	shares
CY2022	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p id="xdx_84B_eus-gaap--ConcentrationRiskCreditRisk_zEhvSqawKkv7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 0.5in"> </td> <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_86B_zqM3po3zIQh7">Concentrations of Credit Risk</span></span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash, accounts receivable, and cash equivalents. The Company generally maintains balances in various operating accounts at financial institutions that management believes to be of high credit quality, in amounts that may exceed federally insured limits. The Company has not experienced any losses related to its cash and cash equivalents and does not believe that it is subject to unusual credit risk beyond the normal credit risk associated with commercial banking relationships.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">When estimating its allowance for credit losses related to revenues from Covid Testing, the Company differentiates its receivables based on the following customer types: healthcare insurers, government payers, and cash payers. Additionally, the Company applies assumptions and judgments for assessing collectability and determining net revenues and accounts receivable from its customers. Historical collection factors we considered for assessing collectability and determining net revenues and accounts receivable from our customers include the period of time that the receivables have been outstanding, history of payment amounts, status of collections due, and applicable statutes of limitations.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">During the year ended June 30, 2022, healthcare insurers and government payers accounted for over <span id="xdx_907_eus-gaap--ConcentrationRiskPercentage1_dp_c20210701__20220630__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__srt--MajorCustomersAxis__custom--HealthcareInsurersAndGovernmentPayersMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zPGFkip61QA" title="Concentrations of credit risk">61</span>% of total revenues. Also, healthcare insurers and government payers amounted to total revenue of $<span id="xdx_906_eus-gaap--Revenues_c20210701__20220630__srt--ProductOrServiceAxis__custom--HealthcareInsurersMember_pp0p0" title="Revenues">11,824,717</span>. The accounts receivable related to both healthcare insurers and government payers is $<span id="xdx_903_eus-gaap--AccountsReceivableNet_c20220630__srt--ProductOrServiceAxis__custom--HealthcareInsurersAndGovernmentPayersMember_pp0p0" title="Accounts Receivable, after Allowance for Credit Loss">4,129,953</span> as of June 30, 2022.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">As of the year ended June 30, 2022, $<span id="xdx_90E_eus-gaap--ContractWithCustomerAssetSale_c20210701__20220630_zmDtYIhPb63j" title="Sale from customer">880,500</span> is owed by a customer from the sale of several Likido units.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"> </p>
CY2022	us-gaap	Contract With Customer Asset Sale ContractWithCustomerAssetSale	880500	usd
CY2022	DFCO	Initial Recognition In Connection With Acquisition Of Deptec InitialRecognitionInConnectionWithAcquisitionOfDeptec	5053000	usd
CY2022	DFCO	Change In Fair Value Of Contingent Consideration ChangeInFairValueOfContingentConsideration	-182200	usd
CY2022Q2	us-gaap	Business Combination Contingent Consideration Liability BusinessCombinationContingentConsiderationLiability	4870800	usd
CY2022	DFCO	Issuance Of Fair Value Of Shares IssuanceOfFairValueOfShares	333333	shares
CY2022Q2	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	119791	usd
CY2021Q2	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	37465	usd
CY2021	us-gaap	Other Depreciation And Amortization OtherDepreciationAndAmortization	28891	usd
CY2021	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	3406684	usd
CY2021	us-gaap	Advertising Expense AdvertisingExpense	563907	usd
CY2022	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	218308	usd
CY2022Q2	us-gaap	Deferred Revenue DeferredRevenue	720923	usd
CY2021Q2	us-gaap	Deferred Revenue DeferredRevenue	219999	usd
CY2022	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	19267613	usd
CY2022Q2	us-gaap	Accounts Receivable Net AccountsReceivableNet	6406555	usd
CY2021Q2	us-gaap	Accounts Receivable Net AccountsReceivableNet	265812	usd
CY2022Q2	us-gaap	Accounts Receivable Related Parties Current AccountsReceivableRelatedPartiesCurrent	41603	usd
CY2021Q2	us-gaap	Accounts Receivable Related Parties Current AccountsReceivableRelatedPartiesCurrent	69952	usd
CY2022Q2	us-gaap	Long Term Investments And Receivables Net LongTermInvestmentsAndReceivablesNet	42395	usd
CY2021Q2	us-gaap	Long Term Investments And Receivables Net LongTermInvestmentsAndReceivablesNet	0	usd
CY2022Q2	DFCO	Longterm Receivables Related Parties LongtermReceivablesRelatedParties	1209103	usd
CY2021Q2	DFCO	Longterm Receivables Related Parties LongtermReceivablesRelatedParties	0	usd
CY2022Q2	us-gaap	Deferred Revenue DeferredRevenue	720923	usd
CY2021Q2	us-gaap	Deferred Revenue DeferredRevenue	219999	usd
CY2022	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	8761266	usd
CY2021	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	2471966	usd
CY2022	us-gaap	Advertising Expense AdvertisingExpense	560777	usd
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	2772770	usd
CY2021	us-gaap	Share Based Compensation ShareBasedCompensation	801672	usd
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	70318073	shares
CY2021	us-gaap	Business Acquisitions Pro Forma Revenue BusinessAcquisitionsProFormaRevenue	4389794	usd
CY2022	us-gaap	Business Acquisitions Pro Forma Net Income Loss BusinessAcquisitionsProFormaNetIncomeLoss	-14169496	usd
CY2021	us-gaap	Business Acquisitions Pro Forma Net Income Loss BusinessAcquisitionsProFormaNetIncomeLoss	174239	usd
CY2022	us-gaap	Business Acquisition Pro Forma Earnings Per Share Basic BusinessAcquisitionProFormaEarningsPerShareBasic	-0.20
CY2021	us-gaap	Business Acquisition Pro Forma Earnings Per Share Basic BusinessAcquisitionProFormaEarningsPerShareBasic	0.00
CY2022	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	15024148	shares
CY2022	DFCO	Contribution Of Property And Equipment Into Joint Venture ContributionOfPropertyAndEquipmentIntoJointVenture	111185	usd
CY2021Q4	us-gaap	Due From Joint Ventures DueFromJointVentures	2104509	usd
CY2022Q2	DFCO	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Common Stock To Be Issued BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationCommonStockToBeIssued	175000	usd
CY2022Q2	us-gaap	Business Combination Contingent Consideration Asset BusinessCombinationContingentConsiderationAsset	5053000	usd
CY2022Q2	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Net BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet	5228000	usd
CY2022Q2	us-gaap	Stock Issued During Period Shares Acquisitions StockIssuedDuringPeriodSharesAcquisitions	1000000	shares
CY2022	us-gaap	Business Acquisitions Pro Forma Revenue BusinessAcquisitionsProFormaRevenue	23723570	usd
CY2022Q2	us-gaap	Inventory Raw Materials InventoryRawMaterials	399706	usd
CY2021Q2	us-gaap	Inventory Raw Materials InventoryRawMaterials	172227	usd
CY2022Q2	us-gaap	Inventory Finished Goods InventoryFinishedGoods	1224915	usd
CY2021Q2	us-gaap	Inventory Finished Goods InventoryFinishedGoods	669881	usd
CY2022Q2	us-gaap	Inventory Net InventoryNet	1624621	usd
CY2021Q2	us-gaap	Inventory Net InventoryNet	842108	usd
CY2022Q2	us-gaap	Machinery And Equipment Gross MachineryAndEquipmentGross	740147	usd
CY2021Q2	us-gaap	Machinery And Equipment Gross MachineryAndEquipmentGross	223141	usd
CY2022Q2	us-gaap	Leasehold Improvements Gross LeaseholdImprovementsGross	314642	usd
CY2021Q2	us-gaap	Leasehold Improvements Gross LeaseholdImprovementsGross	323669	usd
CY2022Q2	us-gaap	Capitalized Computer Software Gross CapitalizedComputerSoftwareGross	518017	usd
CY2021Q2	us-gaap	Capitalized Computer Software Gross CapitalizedComputerSoftwareGross	186549	usd
CY2022Q2	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	1572806	usd
CY2021Q2	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	733359	usd
CY2022Q2	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	496394	usd
CY2021Q2	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	243457	usd
CY2022Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1076412	usd
CY2021Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	489902	usd
CY2022	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	252937	usd
CY2021	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	83606	usd
CY2021Q2	us-gaap	Goodwill Goodwill	736456	usd
CY2022	DFCO	Additions Additions	3735376	usd
CY2022	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	218308	usd
CY2022Q2	us-gaap	Goodwill Goodwill	4253424	usd
CY2021Q2	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	693385	usd
CY2022	DFCO	Finite Lived Intangible Assets Additions FiniteLivedIntangibleAssetsAdditions	2977280	usd
CY2022Q2	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	3670665	usd
CY2021Q2	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	-28891	usd
CY2022	DFCO	Finite Lived Intangible Assets Accumulated Amortization Additions FiniteLivedIntangibleAssetsAccumulatedAmortizationAdditions	-116886	usd
CY2022Q2	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	-145777	usd
CY2022Q2	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	3524888	usd
CY2022	us-gaap	Other Depreciation And Amortization OtherDepreciationAndAmortization	116886	usd
CY2022Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Rolling Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextRollingTwelveMonths	299779	usd
CY2022Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Rolling Year Two FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearTwo	299779	usd
CY2022Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Rolling Year Three FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearThree	299779	usd
CY2022Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Rolling Year Four FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFour	299779	usd
CY2022Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Rolling Year Five FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFive	299779	usd
CY2022Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Rolling After Year Five FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFive	2025993	usd
CY2022Q2	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	3524888	usd
CY2022Q2	us-gaap	Accrued Payroll Taxes Current AccruedPayrollTaxesCurrent	2055736	usd
CY2021Q2	us-gaap	Accrued Payroll Taxes Current AccruedPayrollTaxesCurrent	1953024	usd
CY2022	DFCO	Accrued Interest Rate AccruedInterestRate	Accrued interest is compounded daily at an estimated effective interest rate of 7.33%
CY2022	us-gaap	Income Tax Examination Penalties And Interest Expense IncomeTaxExaminationPenaltiesAndInterestExpense	30155	usd
CY2021	us-gaap	Income Tax Examination Penalties And Interest Expense IncomeTaxExaminationPenaltiesAndInterestExpense	491953	usd
CY2022	DFCO	Gain On Expiration Of Accrued Tax Liabilities GainOnExpirationOfAccruedTaxLiabilities	0	usd
CY2021	DFCO	Gain On Expiration Of Accrued Tax Liabilities GainOnExpirationOfAccruedTaxLiabilities	9054041	usd
CY2022Q2	us-gaap	Notes Payable Related Parties Current And Noncurrent NotesPayableRelatedPartiesCurrentAndNoncurrent	18808062	usd
CY2022Q2	us-gaap	Interest Payable Current And Noncurrent InterestPayableCurrentAndNoncurrent	362855	usd
CY2021Q2	us-gaap	Notes Payable Related Parties Current And Noncurrent NotesPayableRelatedPartiesCurrentAndNoncurrent	10508955	usd
CY2021Q2	us-gaap	Interest Payable Current And Noncurrent InterestPayableCurrentAndNoncurrent	182147	usd
CY2022Q2	us-gaap	Notes Payable Related Parties Classified Current NotesPayableRelatedPartiesClassifiedCurrent	9269377	usd
CY2022Q2	us-gaap	Notes Payable Related Parties Noncurrent NotesPayableRelatedPartiesNoncurrent	9538685	usd
CY2022Q2	us-gaap	Notes Payable Related Parties Current And Noncurrent NotesPayableRelatedPartiesCurrentAndNoncurrent	18808062	usd
CY2022Q2	us-gaap	Long Term Debt Maturities Repayments Of Principal In Next Twelve Months LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths	9269377	usd
CY2022Q2	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Two LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo	2384671	usd
CY2022Q2	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Three LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree	2384671	usd
CY2022Q2	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Four LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour	2384671	usd
CY2022Q2	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Five LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive	2384672	usd
CY2022Q2	us-gaap	Notes Payable Related Parties Current And Noncurrent NotesPayableRelatedPartiesCurrentAndNoncurrent	18808062	usd
CY2022Q2	us-gaap	Notes Payable Current NotesPayableCurrent	669028	usd
CY2021Q2	us-gaap	Notes Payable Current NotesPayableCurrent	415817	usd
CY2022Q2	us-gaap	Long Term Notes Payable LongTermNotesPayable	479001	usd
CY2021Q2	us-gaap	Long Term Notes Payable LongTermNotesPayable	0	usd
CY2022Q2	us-gaap	Notes Payable NotesPayable	1148029	usd
CY2021Q2	us-gaap	Notes Payable NotesPayable	415817	usd
CY2022	us-gaap	Debt Instrument Periodic Payment DebtInstrumentPeriodicPayment	3320	usd
CY2022Q2	us-gaap	Debt Instrument Periodic Payment Terms Balloon Payment To Be Paid DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid	466460	usd
CY2022	us-gaap	Line Of Credit Facility Interest Rate Description LineOfCreditFacilityInterestRateDescription	interest rate of Prime + 1%
CY2022	us-gaap	Debt Instrument Maturity Date DebtInstrumentMaturityDate	2021-05-05
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	8730936	shares
CY2022Q2	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	600000	usd
CY2022	DFCO	Redemption Premium In Cash RedemptionPremiumInCash	60000	usd
CY2022	DFCO	Redemption Premium In Stock RedemptionPremiumInStock	20000	usd
CY2022	DFCO	Interest Accretion InterestAccretion	120000	usd
CY2022	DFCO	Debenture In Cash DebentureInCash	300000	usd
CY2022	DFCO	Debenture In Stock DebentureInStock	100000	usd
CY2022	us-gaap	Stock Redeemed Or Called During Period Shares StockRedeemedOrCalledDuringPeriodShares	373436	shares
CY2021	us-gaap	Management Fee Expense ManagementFeeExpense	72000	usd
CY2022Q2	us-gaap	Accounts Payable Related Parties Current And Noncurrent AccountsPayableRelatedPartiesCurrentAndNoncurrent	417237	usd
CY2020Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	0
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod	1000000	shares
CY2021	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	0.47
CY2021	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	0	shares
CY2021	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	0
CY2021	us-gaap	Stock Issued During Period Shares Share Based Compensation Forfeited StockIssuedDuringPeriodSharesShareBasedCompensationForfeited	0	shares
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice	0
CY2022	us-gaap	Revenue From Related Parties RevenueFromRelatedParties	1403056	usd
CY2021	us-gaap	Revenue From Related Parties RevenueFromRelatedParties	332657	usd
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	0.45
CY2022	us-gaap	Preferred Stock Conversion Basis PreferredStockConversionBasis	The Series G Stock shall convert at one share of Series G Stock to 2,177 shares of common stock (equivalent to converting the related dollars into common shares at $0.30 per share).
CY2021Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized	4500000	shares
	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	730000	usd
CY2022Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	72174620	shares
CY2022Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	72174620	shares
CY2021Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	73838662	shares
CY2021Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	73838662	shares
CY2022Q1	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	0.45
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	0.59
CY2022Q1	DFCO	Fair Value Of Options Granted FairValueOfOptionsGranted	1338644	usd
CY2020Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	0	shares
CY2021Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	1000000	shares
CY2021Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	0
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod	12025000	shares
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	0.45
CY2022	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	0	shares
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	0
CY2022	us-gaap	Stock Issued During Period Shares Share Based Compensation Forfeited StockIssuedDuringPeriodSharesShareBasedCompensationForfeited	0	shares
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice	0
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	12025000	shares
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	0.45
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0114	pure
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0080	pure
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	1.492	pure
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	1.4920	pure
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0.0000	pure
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0.0000	pure
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P5Y3M7D
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P5Y3M7D
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	0	usd
CY2021Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	0	usd
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	2772770	usd
CY2021	us-gaap	Share Based Compensation ShareBasedCompensation	801672	usd
CY2022Q2	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	1690423	usd
CY2022	us-gaap	Revenues Revenues	19267613	usd
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-10435244	usd
CY2021	us-gaap	Revenues Revenues	3406684	usd
CY2021	us-gaap	Operating Income Loss OperatingIncomeLoss	-8570151	usd
CY2022Q2	us-gaap	Operating Lease Liability OperatingLeaseLiability	2754594	usd
CY2022Q2	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	26089624	usd
CY2022	us-gaap	Operating Loss Carryforwards Limitations On Use OperatingLossCarryforwardsLimitationsOnUse	begin to expire in 2038 through 2041
CY2021Q2	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	2940788	usd
CY2022Q2	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	5801923	usd
CY2021Q2	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	2940788	usd
CY2022	us-gaap	Revenues Revenues	19267613	usd
CY2021	us-gaap	Revenues Revenues	3406684	usd
CY2022Q2	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	0	usd
CY2021Q2	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	0	usd
CY2022Q2	us-gaap	Inventory Net InventoryNet	1624621	usd
CY2021Q2	us-gaap	Inventory Net InventoryNet	842108	usd
CY2022Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1076412	usd
CY2021Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	489902	usd
CY2022Q2	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	819462	usd
CY2022Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	799259	usd
CY2022Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	636955	usd
CY2022Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	273221	usd
CY2022Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	225169	usd
CY2022Q2	us-gaap	Lessee Operating Lease Liability Payments Due After Year Five LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive	221488	usd
CY2022Q2	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	2975554	usd
CY2022Q2	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	220960	usd
CY2022	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	0	usd
CY2021	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	0	usd
CY2022	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	0	usd
CY2021	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	0	usd
CY2022	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	132513	usd
CY2021	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	0	usd
CY2022	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	132513	usd
CY2022	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	2239061	usd
CY2021	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	1607556	usd
CY2022	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	622074	usd
CY2021	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	446626	usd
CY2022	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-2861136	usd
CY2021	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-2054182	usd
CY2022	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	2861135	usd
CY2021	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	2054182	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	132513	usd
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2022Q2	us-gaap	Deferred Tax Assets Tax Deferred Expense Other DeferredTaxAssetsTaxDeferredExpenseOther	30382	usd
CY2021Q2	us-gaap	Deferred Tax Assets Tax Deferred Expense Other DeferredTaxAssetsTaxDeferredExpenseOther	1521	usd
CY2022Q2	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals	122154	usd
CY2021Q2	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals	250907	usd
CY2022Q2	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	0	usd
CY2021Q2	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	0	usd
CY2022Q2	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	5649387	usd
CY2021Q2	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	2688360	usd
CY2022Q2	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	5801923	usd
CY2022	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210	pure
CY2021	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.044	pure
CY2021	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	-364.23	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	0.009	pure
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	-0.0000	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Tax Settlements Other EffectiveIncomeTaxRateReconciliationTaxSettlementsOther	-0.002	pure
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Tax Settlements Other EffectiveIncomeTaxRateReconciliationTaxSettlementsOther	-1557.21	pure
CY2022	DFCO	Effective Income Tax Rate Reconciliation Gain On Expiration Of Accrued Tax Liability EffectiveIncomeTaxRateReconciliationGainOnExpirationOfAccruedTaxLiability	0.00	pure
CY2021	DFCO	Effective Income Tax Rate Reconciliation Gain On Expiration Of Accrued Tax Liability EffectiveIncomeTaxRateReconciliationGainOnExpirationOfAccruedTaxLiability	10224	pure
CY2022	DFCO	Effective Income Tax Rate Reconciliation Stock Based Compensation EffectiveIncomeTaxRateReconciliationStockBasedCompensation	-0.041	pure
CY2021	DFCO	Effective Income Tax Rate Reconciliation Stock Based Compensation EffectiveIncomeTaxRateReconciliationStockBasedCompensation	102.24	pure
CY2022	DFCO	Effective Income Tax Rate Reconciliation Nondeductible Interest EffectiveIncomeTaxRateReconciliationNondeductibleInterest	0.008	pure
CY2021	DFCO	Effective Income Tax Rate Reconciliation Nondeductible Interest EffectiveIncomeTaxRateReconciliationNondeductibleInterest	-0.0000	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.203	pure
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	1685.22	pure
CY2022	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	-0.009	pure
CY2021	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	1.966	pure

Files In Submission

Name	View Source	Status
0001683168-22-007171-index-headers.html	Edgar Link	pending
0001683168-22-007171-index.html	Edgar Link	pending
0001683168-22-007171.txt	Edgar Link	pending
0001683168-22-007171-xbrl.zip	Edgar Link	pending
dalrada_ex3101.htm	Edgar Link	pending
dalrada_ex3201.htm	Edgar Link	pending
dalrada_i10k-063022.htm	Edgar Link	pending
dfco-20220630.xsd	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
dfco-20220630_lab.xml	Edgar Link	unprocessable
dfco-20220630_pre.xml	Edgar Link	unprocessable
dalrada_i10k-063022_htm.xml	Edgar Link	completed
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R75.htm	Edgar Link	pending
R76.htm	Edgar Link	pending
R77.htm	Edgar Link	pending
R78.htm	Edgar Link	pending
R79.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
dfco-20220630_cal.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
dfco-20220630_def.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$DFCO
DALRADA FINANCIAL CORP Stock $dfco

2022 Q3 Form 10-K Financial Statement

#000168316822007171 Filed on November 01, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$DFCO DALRADA FINANCIAL CORP Stock $dfco

2022 Q3 Form 10-K Financial Statement

#000168316822007171 Filed on November 01, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$DFCO
DALRADA FINANCIAL CORP Stock $dfco